Sukhmani K Padda1, Xiaopan Yao2, Alberto Antonicelli2, Jonathan W Riess3, Yue Shang4, Joseph B Shrager5, Robert Korst6, Frank Detterbeck2, James Huang7, Bryan M Burt8, Heather A Wakelee9, Sunil S Badve10. 1. Department of Medicine, Division of Oncology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California. Electronic address: padda@stanford.edu. 2. Department of Surgery, Division of Thoracic Surgery, Yale University School of Medicine, New Haven, Connecticut. 3. Department of Medicine, Division of Oncology, University of California Davis Cancer Center, Sacramento, California. 4. The MathWorks, Natick, Massachusetts. 5. Department of Cardiothoracic Surgery, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California. 6. Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai Health System, New York, New York; Valley/Mount Sinai Comprehensive Cancer Care, Paramus, New Jersey. 7. Department of Surgery, Thoracic Service, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Department of Surgery, Division of Thoracic Surgery, Baylor College of Medicine, Houston, Texas. 9. Department of Medicine, Division of Oncology, Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California. 10. Department of Pathology, Indiana University, Indianapolis, Indiana.
Abstract
INTRODUCTION: Thymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs. METHODS: The International Thymic Malignancy Interest Group retrospective database was examined to determine (1) baseline and treatment characteristics associated with PN/AI syndromes and (2) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards model was used for multivariate analysis. RESULTS: A total of 6670 patients with known PN/AI syndrome status from 1951 to 2012 were identified. PN/AI syndromes were associated with younger age, female sex, thymoma histologic type, earlier stage, and an increased rate of total thymectomy and complete resection status. There was a statistically significant lower CIR in the group with a PN/AI syndrome than in the group without a PN/AI syndrome (10-year CIR 17.3% versus 21.2%, respectively [p = 0.0003]). The OS was improved in the group with a PN/AI syndrome compared to the group without a PN/AI syndrome (median OS 21.6 years versus 17.0 years, respectively [hazard ratio = 0.63, 95% confidence interval: 0.54-0.74, p < 0.0001]). However, in the multivariate model for recurrence-free survival and OS, PN/AI syndrome was not an independent prognostic factor. DISCUSSION: Previously, there have been mixed data regarding the prognostic role of PN/AI syndromes for patients with TETs. Here, using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features (i.e., earlier stage and complete resection status) but were not an independent prognostic factor for patients with TETs.
INTRODUCTION: Thymic epithelial tumors (TETs) are associated with paraneoplastic/autoimmune (PN/AI) syndromes. Myasthenia gravis is the most common PN/AI syndrome associated with TETs. METHODS: The International Thymic Malignancy Interest Group retrospective database was examined to determine (1) baseline and treatment characteristics associated with PN/AI syndromes and (2) the prognostic role of PN/AI syndromes for patients with TETs. The competing risks model was used to estimate cumulative incidence of recurrence (CIR) and the Kaplan-Meier method was used to calculate overall survival (OS). A Cox proportional hazards model was used for multivariate analysis. RESULTS: A total of 6670 patients with known PN/AI syndrome status from 1951 to 2012 were identified. PN/AI syndromes were associated with younger age, female sex, thymoma histologic type, earlier stage, and an increased rate of total thymectomy and complete resection status. There was a statistically significant lower CIR in the group with a PN/AI syndrome than in the group without a PN/AI syndrome (10-year CIR 17.3% versus 21.2%, respectively [p = 0.0003]). The OS was improved in the group with a PN/AI syndrome compared to the group without a PN/AI syndrome (median OS 21.6 years versus 17.0 years, respectively [hazard ratio = 0.63, 95% confidence interval: 0.54-0.74, p < 0.0001]). However, in the multivariate model for recurrence-free survival and OS, PN/AI syndrome was not an independent prognostic factor. DISCUSSION: Previously, there have been mixed data regarding the prognostic role of PN/AI syndromes for patients with TETs. Here, using the largest data set in the world for TETs, PN/AI syndromes were associated with favorable features (i.e., earlier stage and complete resection status) but were not an independent prognostic factor for patients with TETs.
Authors: Bryan M Burt; Xiaopan Yao; Joseph Shrager; Alberto Antonicelli; Sukhmani Padda; Jonathan Reiss; Heather Wakelee; Stacey Su; James Huang; Walter Scott Journal: J Thorac Oncol Date: 2016-08-24 Impact factor: 15.609
Authors: C Bernard; H Frih; F Pasquet; S Kerever; Y Jamilloux; F Tronc; B Guibert; S Isaac; M Devouassoux; L Chalabreysse; C Broussolle; P Petiot; N Girard; P Sève Journal: Autoimmun Rev Date: 2015-09-25 Impact factor: 9.754
Authors: P Szczudlik; B Szyluk; M Lipowska; B Ryniewicz; J Kubiszewska; M Dutkiewicz; N E Gilhus; A Kostera-Pruszczyk Journal: Acta Neurol Scand Date: 2014-06-20 Impact factor: 3.209
Authors: Geir Olve Skeie; Ase Mygland; Susan Treves; Nils Erik Gilhus; Johan Arild Aarli; Francesco Zorzato Journal: Muscle Nerve Date: 2003-01 Impact factor: 3.217
Authors: Hengrui Liang; Lujiao Ye; Wenhua Liang; Runchen Wang; Fan Ge; Lihua Fan; Yao Zhu; Grace S Li; Stephen D Wang; Kevin Phan; Alan Sihoe; Kaiping Zhang; Jianxing He Journal: Ann Transl Med Date: 2019-12
Authors: Fernando Guerrero-Pérez; Inmaculada Peiró; Agustina Pia Marengo; Alex Teulé; José Carlos Ruffinelli; Roger Llatjos; Teresa Serrano; Ivan Macia; Nuria Vilarrasa; Pedro Iglesias; Carles Villabona Journal: Rev Endocr Metab Disord Date: 2021-05-07 Impact factor: 6.514